620 related articles for article (PubMed ID: 19707983)
1. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.
Pretorius M; Murphey LJ; McFarlane JA; Vaughan DE; Brown NJ
Circulation; 2003 Dec; 108(25):3079-83. PubMed ID: 14656921
[TBL] [Abstract][Full Text] [Related]
3. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction.
Boman KO; Jansson JH; Nyhlén KA; Nilsson TK
Thromb Haemost; 2002 Feb; 87(2):311-6. PubMed ID: 11859853
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
5. The kinetics of plasmin inhibition by aprotinin in vivo.
Kang HM; Kalnoski MH; Frederick M; Chandler WL
Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
[TBL] [Abstract][Full Text] [Related]
6. Vitamin E improves fibrinolytic activity in patients with coronary spastic angina.
Miyamoto S; Kawano H; Takazoe K; Soejima H; Sakamoto T; Hokamaki J; Yoshimura M; Nakamura H; Yodoi J; Ogawa H
Thromb Res; 2004; 113(6):345-51. PubMed ID: 15226088
[TBL] [Abstract][Full Text] [Related]
7. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
Usalan C; Buyukhatipoglu H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
[TBL] [Abstract][Full Text] [Related]
8. Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: a prospective randomized study.
Paulitsch FS; Schneider D; Sobel BE; Rached R; Ramires J; Jatene F; Stolf N; Hueb W; Lopes NH
Coron Artery Dis; 2009 Mar; 20(2):100-5. PubMed ID: 19293667
[TBL] [Abstract][Full Text] [Related]
9. Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction.
Moriyama Y; Ogawa H; Oshima S; Arai H; Takazoe K; Shimomura H; Hirai N; Suefuji H; Soejima H; Nishiyama K; Misumi K; Yasue H
Coron Artery Dis; 1998; 9(10):691-6. PubMed ID: 9894621
[TBL] [Abstract][Full Text] [Related]
10. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
12. Influence of ACE inhibition on myocardial damage, the Kallikrein-Kinin system and hemostasis during cardiopulmonary bypass surgery.
Walter T; Helber U; Bail D; Heller W; Hoffmeister HM
Thorac Cardiovasc Surg; 2002 Jun; 50(3):150-4. PubMed ID: 12077687
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
14. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
[TBL] [Abstract][Full Text] [Related]
15. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction?
Tsikouris JP; Suarez JA; Meyerrose GE; Ziska M; Fike D; Smith J
J Clin Pharmacol; 2004 Feb; 44(2):150-7. PubMed ID: 14747423
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
Pedersen OD; Gram J; Jespersen J
Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
19. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
20. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]